{
    "xml": "<topic id=\"PHP88082\" outputclass=\"drug\" rev=\"1.24\" type=\"drug\" namespace=\"/drugs/carbidopa-with-entacapone-and-levodopa\" basename=\"carbidopa-with-entacapone-and-levodopa\" title=\"CARBIDOPA WITH ENTACAPONE AND LEVODOPA\">\n<title>CARBIDOPA WITH ENTACAPONE AND LEVODOPA </title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_980\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/co-careldopa\">Co-careldopa</xref>, <xref format=\"dita\" href=\"#bnf_int_854\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/entacapone\">Entacapone</xref>\n</p>\r\n<p outputclass=\"constituentDrugs\">The properties listed below are those particular to the combination only. For the properties of the components please consider, <xref format=\"dita\" href=\"#PHP3122\" namespace=\"/drugs/entacapone\">entacapone</xref>, <xref format=\"dita\" href=\"#PHP3098\" namespace=\"/drugs/co-careldopa\">co-careldopa</xref>.</p>\n<data name=\"vtmid\">410860008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_629748644\" title=\"Dopa-decarboxylase inhibitors\">Dopa-decarboxylase inhibitors</xref>\n</data>\n</data>\r\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_743470528\" title=\"Catechol-o-methyltransferase inhibitors\">Catechol-o-methyltransferase inhibitors</xref>\n</data>\n</data>\r\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_314874326\" title=\"Dopamine precursors\">Dopamine precursors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP90803\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/carbidopa-with-entacapone-and-levodopa\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patients receiving standard-release co-careldopa or co-beneldopa alone, initiate <i>Stalevo</i>\n<tm tmtype=\"reg\"/> at a dose that provides similar (or slightly lower) amount of levodopa.</p>\n<p>Patients with dyskinesia or receiving more than 800&#8239;mg levodopa daily, introduce entacapone before transferring to <i>Stalevo</i>\n<tm tmtype=\"reg\"/> (levodopa dose may need to be reduced by 10&#8211;30% initially).</p>\n<p>Patients receiving entacapone and standard-release co-careldopa or co-beneldopa, initiate<i>Stalevo</i>\n<tm tmtype=\"reg\"/> at a dose that provides similar (or slightly higher) amount of levodopa.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP90792\" outputclass=\"patientAndCarerAdvice\" rev=\"1.11\" parent=\"/drugs/carbidopa-with-entacapone-and-levodopa\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p outputclass=\"title\">Sudden onset of sleep</p>\n<p>Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa.</p>\n<p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p>\n<p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP88082-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/carbidopa-with-entacapone-and-levodopa\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP92413\" title=\"Tablet\" namespace=\"/drugs/carbidopa-with-entacapone-and-levodopa/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"3\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_980\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/co-careldopa\" title=\"Co-careldopa\" count=\"1\" rel=\"link\">Co-careldopa</xref>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_854\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/entacapone\" title=\"Entacapone\" count=\"1\" rel=\"link\">Entacapone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3122\" namespace=\"/drugs/entacapone\" title=\"ENTACAPONE\" count=\"1\" rel=\"link\">ENTACAPONE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3098\" namespace=\"/drugs/co-careldopa\" title=\"CO-CARELDOPA\" count=\"1\" rel=\"link\">CO-CARELDOPA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP92413\" namespace=\"/drugs/carbidopa-with-entacapone-and-levodopa/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP88082",
    "outputclass": "drug",
    "rev": "1.24",
    "type": "drug",
    "namespace": "/drugs/carbidopa-with-entacapone-and-levodopa",
    "basename": "carbidopa-with-entacapone-and-levodopa",
    "title": "CARBIDOPA WITH ENTACAPONE AND LEVODOPA",
    "interactants": [
        {
            "id": "bnf_int_980",
            "label": "Co-careldopa"
        },
        {
            "id": "bnf_int_854",
            "label": "Entacapone"
        }
    ],
    "constituents": [
        {
            "id": "PHP3122",
            "label": "entacapone"
        },
        {
            "id": "PHP3098",
            "label": "co-careldopa"
        }
    ],
    "vtmid": "410860008",
    "drugClassification": [
        "Dopa-decarboxylase inhibitors",
        "Catechol-o-methyltransferase inhibitors",
        "Dopamine precursors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Patients receiving standard-release co-careldopa or co-beneldopa alone, initiate Stalevo at a dose that provides similar (or slightly lower) amount of levodopa.\n\nPatients with dyskinesia or receiving more than 800 mg levodopa daily, introduce entacapone before transferring to Stalevo (levodopa dose may need to be reduced by 10&#8211;30% initially).\n\nPatients receiving entacapone and standard-release co-careldopa or co-beneldopa, initiateStalevo at a dose that provides similar (or slightly higher) amount of levodopa.",
                "html": "<p>Patients receiving standard-release co-careldopa or co-beneldopa alone, initiate <i>Stalevo</i>\n<tm tmtype=\"reg\"/> at a dose that provides similar (or slightly lower) amount of levodopa.</p><p>Patients with dyskinesia or receiving more than 800&#8239;mg levodopa daily, introduce entacapone before transferring to <i>Stalevo</i>\n<tm tmtype=\"reg\"/> (levodopa dose may need to be reduced by 10&#8211;30% initially).</p><p>Patients receiving entacapone and standard-release co-careldopa or co-beneldopa, initiate<i>Stalevo</i>\n<tm tmtype=\"reg\"/> at a dose that provides similar (or slightly higher) amount of levodopa.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Sudden onset of sleep",
                "textContent": "Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa.\n\nPatients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.\n\nManagement of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.",
                "html": "<p>Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP92413",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_980",
                "label": "Co-careldopa",
                "type": "interaction"
            },
            {
                "id": "bnf_int_854",
                "label": "Entacapone",
                "type": "interaction"
            }
        ],
        "drug": [
            {
                "id": "PHP3122",
                "label": "ENTACAPONE",
                "type": "drug"
            },
            {
                "id": "PHP3098",
                "label": "CO-CARELDOPA",
                "type": "drug"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP92413",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}